Eton Pharmaceuticals (ETON) vs Harrow (HROW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Harrow (HROW) over the past year, gaining 159.5% versus a loss of 26.9%. Over five years, ETON leads with a +953.4% price change compared with +209.6% for HROW. Eton Pharmaceuticals is the larger company by market cap ($1.57 billion vs $1.15 billion), about 1.4 times the size.
On valuation, Harrow trades at a lower forward P/E (11.0x vs 21.3x for Eton Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | HROW |
|---|---|---|
| Share price | $54.88 | $30.62 |
| Market cap | $1.57B | $1.15B |
| 1-day change | +0.20% | +0.89% |
| YTD return | +224.54% | -37.51% |
| 1-year return | +159.48% | -26.92% |
| 5-year return | +953.36% | +209.61% |
| P/E ratio (TTM) | 137.20 | — |
| Forward P/E | 21.27 | 11.04 |
| EPS (TTM) | $0.40 | $-0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $66.37 | $54.85 |
| 52-week low | $14.27 | $28.54 |
| Distance from 52-week high | -17.31% | -44.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.37% | +112.28% |
| Average volume | 603.39K | 552.72K |
| Shares outstanding | 28.58M | 37.49M |
| Employees | 44 | 373 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed HROW by 186.4 percentage points over the past year.
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
ETON vs HROW FAQ
Which is bigger, Eton Pharmaceuticals or Harrow?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.57B compared with $1.15B for Harrow (HROW).
Which stock has performed better over the past year, ETON or HROW?
ETON returned +159.48% over the past 12 months, compared with -26.92% for HROW (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and Harrow in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.